Clinical Trials Browser

Phase 1/2 × Myelodysplastic Syndromes × GSK-3326595 × Clear all

NCT03614728 2023-02-06

Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Phase 1/2 Terminated

30 enrolled 29 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic